Ocular Therapeutix (OCUL) Poised to Recover as Dextenza Grows 50% Sequentially - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $28.00 price target on Ocular Therapeutix (NASDAQ: OCUL) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
